Castle Biosciences’ (CSTL) Buy Rating Reiterated at Canaccord Genuity Group
Castle Biosciences (NASDAQ: CSTL) received a resounding vote of confidence this week when Canaccord Genuity Group reaffirmed its “buy” rating. The firm’s price objective of $37.00 points to a potential 61.29% upside for the company’s shares.
21 hours ago
1 min read
